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1. INTRODUCTION {#apt15245-sec-0006}
===============

Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and usually develops in patients suffering from underlying chronic liver disease.[1](#apt15245-bib-0001){ref-type="ref"}, [2](#apt15245-bib-0002){ref-type="ref"}, [3](#apt15245-bib-0003){ref-type="ref"}, [4](#apt15245-bib-0004){ref-type="ref"}, [5](#apt15245-bib-0005){ref-type="ref"} Despite recommendations for surveillance of patients at risk, HCC is often diagnosed at an advanced stage where only systemic treatment can be offered. Many patients develop recurrence or disease progression after initial surgical or loco‐regional treatment and then become candidates for palliative systemic therapy.[1](#apt15245-bib-0001){ref-type="ref"}, [5](#apt15245-bib-0005){ref-type="ref"}, [6](#apt15245-bib-0006){ref-type="ref"} For the last decade, the tyrosine kinase inhibitor sorafenib was the only effective drug available for HCC,[6](#apt15245-bib-0006){ref-type="ref"} with two randomised controlled phase III trials showing a survival benefit compared to placebo.[7](#apt15245-bib-0007){ref-type="ref"}, [8](#apt15245-bib-0008){ref-type="ref"} Only recently, three more tyrosine kinase inhibitors were approved for HCC, lenvatinib in first‐line and regorafenib and cabozantinib in second‐line drug treatment.[9](#apt15245-bib-0009){ref-type="ref"}, [10](#apt15245-bib-0010){ref-type="ref"}, [11](#apt15245-bib-0011){ref-type="ref"} Ramucirumab, a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR)‐2, improved survival in a second‐line phase III study of patients with advanced HCC and elevated alpha‐fetoprotein,[12](#apt15245-bib-0012){ref-type="ref"} and thus will likely be included in the treatment algorithm shortly.

Immunotherapy with checkpoint blockers demonstrated encouraging efficacy in certain cancer types, particularly in melanoma and lung cancer.[13](#apt15245-bib-0013){ref-type="ref"} HCC may also be an attractive candidate for immunotherapy, as it represents an immunogenic tumour, but also fosters an immunosuppressive microenvironment (eg, by up‐regulation of immune checkpoint molecules). This may be further supported by the tolerogenic liver milieu and chronic inflammation due to the underlying liver disease.[6](#apt15245-bib-0006){ref-type="ref"}, [14](#apt15245-bib-0014){ref-type="ref"}, [15](#apt15245-bib-0015){ref-type="ref"}, [16](#apt15245-bib-0016){ref-type="ref"} Notably, overexpression of the checkpoint molecules programmed cell death‐ligand 1 (PD‐L1) and programmed cell death protein‐1 (PD‐1) was associated with tumour aggressiveness and postoperative recurrence in HCC.[17](#apt15245-bib-0017){ref-type="ref"}, [18](#apt15245-bib-0018){ref-type="ref"}

Nivolumab and pembrolizumab, two monoclonal antibodies against PD‐1, have shown promising efficacy and safety results in noncomparative, open‐label phase II studies of advanced HCC,[19](#apt15245-bib-0019){ref-type="ref"}, [20](#apt15245-bib-0020){ref-type="ref"} and the United States Food and Drug Administration (FDA) already granted accelerated conditional approval to both agents for sorafenib‐experienced patients with HCC. Both nivolumab and pembrolizumab are currently being investigated in ongoing phase III trials.

In the present study, we aimed to analyse the safety and efficacy of anti‐PD‐1 targeted therapy with nivolumab or pembrolizumab in an international, multicentre, real‐life cohort of patients with advanced HCC. In contrast to the phase II studies of nivolumab and pembrolizumab,[19](#apt15245-bib-0019){ref-type="ref"}, [20](#apt15245-bib-0020){ref-type="ref"} our cohort also includes patients with more advanced liver cirrhosis (Child‐Pugh B/C) as well as patients who received immunotherapy as third or even fourth line of systemic therapy. Thus, this cohort reflects the treatment reality in advanced HCC outside of clinical trial programs.

2. PATIENTS AND METHODS {#apt15245-sec-0007}
=======================

2.1. Study design and patients {#apt15245-sec-0008}
------------------------------

This was a retrospective study of patients treated with nivolumab or pembrolizumab across six centres in Austria and Germany. Patients with histologically or radiologically confirmed HCC[1](#apt15245-bib-0001){ref-type="ref"} who received PD‐1‐targeted immunotherapy with nivolumab or pembrolizumab were eligible. All data, including patient history, laboratory results and radiological information were collected retrospectively. The retrospective analysis was approved by local Ethics Committees.

2.2. Dosing of nivolumab and pembrolizumab {#apt15245-sec-0009}
------------------------------------------

Nivolumab was administered at 1‐3 mg/kg body weight or at a fixed dose of 240 mg every 2 weeks intravenously. Pembrolizumab was given at 2 mg/kg body weight or at a fixed dose of 200 mg every 3 weeks intravenously. Dose delays were made based on toxicity.

2.3. Assessments {#apt15245-sec-0010}
----------------

Radiological response was recorded by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, 6‐12 weeks after treatment initiation, and about every 3 months thereafter. Tumour response was assessed according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST).[21](#apt15245-bib-0021){ref-type="ref"} Patients with progressive disease of target lesions (increase of at least 20%) at the first radiological evaluation were assessed for hyperprogressive disease. Hyperprogression was defined as a progressive disease (RECIST version 1.1[22](#apt15245-bib-0022){ref-type="ref"}) on the first radiological evaluation during immunotherapy with a delta tumour growth rate of \> 50%, corresponding to an absolute increase in tumour growth rate exceeding 50% per month.[23](#apt15245-bib-0023){ref-type="ref"} Tumour growth rate was calculated as described previously,[23](#apt15245-bib-0023){ref-type="ref"} and delta tumour growth rate (tumour growth rate during immunotherapy minus tumour growth rate before immunotherapy) was then used to assess the association of immunotherapy with tumour growth. Tumour growth rate was only quantified for target lesions.[23](#apt15245-bib-0023){ref-type="ref"} To calculate tumour growth rate before and during immunotherapy, images of CT/MRI scans were required from three different time points: (a) before baseline (while patient was receiving prior therapy/no therapy), (b) at baseline (before initiation of immunotherapy), (c) at first evaluation during immunotherapy. Hence, hyperprogressive disease could only be calculated in patients of whom radiographic images were available from all three above mentioned time points.

Side effects were recorded at every visit and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.

2.4. Statistics {#apt15245-sec-0011}
---------------

Data on baseline characteristics, radiological tumour response and side effects were summarised using descriptive statistics. Chi square test or Fisher\'s exact test were used to compare nominal data. We avoided statistical comparison between nivolumab‐ and pembrolizumab‐treated patients as this would be unreliable due to the retrospective study design. Median duration of treatment was defined as time from the date of the first administration until the date of last infusion. Patients who were still receiving immunotherapy at data cut‐off were censored. Patients who had at least one follow‐up imaging assessment were evaluable for radiological response and time to progression. Time to progression (TTP) was defined as the time from the date of first checkpoint inhibitor administration until the date of first radiologically confirmed tumour progression. Data from patients who died without radiologically confirmed tumour progression were censored at the date of last radiological assessment. Progression‐free survival (PFS) was defined as the time from the date of first checkpoint inhibitor administration until radiological disease progression or death, whatever came first. Patients who were still alive and without radiologically confirmed progression were censored at the date of last contact or data cut‐off. Overall survival (OS) was defined as the time from start of immunotherapy until the date of death. Patients who were still alive were censored at the date of last contact or data cut‐off. Survival curves were calculated using the Kaplan‐Meier method and compared by means of the log rank test. Statistical analyses were performed using IBM SPSS Statistics version 25 (SPSS Inc., Chicago, IL). A *P* \< 0.05 was considered significant.

3. RESULTS {#apt15245-sec-0012}
==========

3.1. Patients {#apt15245-sec-0013}
-------------

Sixty‐five patients in whom PD‐1 targeted immunotherapy was initiated between July 10, 2015 and April 27, 2018 were included. The date of data cut‐off was December 31, 2018. Thirty‐four subjects received nivolumab and 31 patients were treated with pembrolizumab (Figure [1](#apt15245-fig-0001){ref-type="fig"}). Main baseline characteristics are shown in Table [1](#apt15245-tbl-0001){ref-type="table"}. Immunotherapy was used as systemic first‐, second‐, third‐, or fourth‐line treatment in 9 (14%), 27 (42%), 26 (40%) and 3 (5%) patients respectively. Agents used for prior systemic therapy are shown in Table [S1](#apt15245-sup-0001){ref-type="supplementary-material"}. Fifty‐one (79%) patients had advanced stage HCC and a significant number of patients had Child‐Pugh stage B/C (n = 33; 51%).

![Patient flow chart](APT-49-1323-g001){#apt15245-fig-0001}

###### 

Baseline characteristics

                                          Nivolumab, n = 34   Pembrolizumab, n = 31   All patients, n = 65
  --------------------------------------- ------------------- ----------------------- ----------------------
  Age (y), mean ± SD                      64.0 ± 10.6         66.5 ± 11.7             65.2 ± 11.1
  Sex                                                                                 
  Male                                    24 (71%)            25 (81%)                49 (75%)
  Female                                  10 (29%)            6 (19%)                 16 (25%)
  Aetiology                                                                           
  Alcohol                                 5 (15%)             14 (45%)                19 (29%)
  Hepatitis C                             8 (24%)             2 (6%)                  10 (15%)
  Hepatitis B                             5 (15%)             3 (10%)                 8 (12%)
  NAFLD                                   8 (24%)             3 (10%)                 11 (7%)
  Other                                   8 (24%)             9 (29%)                 17 (26%)
  Child‐Pugh stage                                                                    
  A                                       17 (50%)            15 (48%)                32 (49%)
  B                                       14 (41%)            14 (45%)                28 (43%)
  C                                       3 (9%)              2 (6%)                  5 (8%)
  ECOG PS                                                                             
  0                                       16 (47%)            16 (52%)                32 (49%)
  ≥1                                      18 (53%)            15 (48%)                33 (51%)
  Prior treatment                                                                     
  Surgery                                 8 (24%)             7 (23%)                 15 (23%)
  Ablation                                5 (15%)             4 (13%)                 9 (14%)
  Loco‐regional (TACE, SIRT, radiation)   12 (35%)            18 (58%)                30 (46%)
  Systemic                                28 (82%)            28 (90%)                56 (86%)
  Previous sorafenib                      28 (82%)            28 (90%)                56 (86%)
  Previous regorafenib                    10 (29%)            15 (48%)                25 (38%)
  Immunotherapy as systemic                                                           
  First‐line                              6 (18%)             3 (10%)                 9 (14%)
  Second‐line                             17 (50%)            10 (32%)                27 (42%)
  Third‐line                              9 (27%)             17 (55%)                26 (40%)
  Fourth‐line                             2 (6%)              1 (3%)                  3 (5%)
  Macrovascular invasion                  13 (38%)            11 (36%)                24 (37%)
  Extrahepatic metastasis                 21 (62%)            14 (45%)                35 (54%)
  BCLC stage                                                                          
  B                                       2 (6%)              6 (19%)                 8 (12%)
  C                                       28 (82%)            23 (74%)                51 (79%)
  D                                       4 (12%)             2 (6%)                  6 (9%)
  Alpha‐Fetoprotein                                                                   
  \<400 (IU/ml)                           20 (59%)            16 (52%)                36 (55%)
  ≥400 (IU/ml)                            13 (38%)            15 (48%)                28 (43%)

BCLC, Barcelona‐Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NAFLD, non‐alcoholic fatty liver disease; SIRT, selective internal radiotherapy; TACE, transarterial chemoembolisation.

John Wiley & Sons, Ltd

Median duration of follow‐up was 11.2 (95% CI, 9.9‐12.6) months. Median time of treatment was 3.1 (95% CI, 2.5‐3.6) months for nivolumab and 2.8 (95% CI, 0‐5.7) months for pembrolizumab. At data cut‐off, 2 (6%) and 9 (29%) patients were still on treatment with nivolumab and pembrolizumab respectively. Immunotherapy was discontinued mainly due to radiological or clinical disease progression (nivolumab and pembrolizumab, n = 23 (68%) and n = 14 (45%)) and adverse events (nivolumab and pembrolizumab, n = 6 (18%) and n = 1 (3%)). After discontinuation of immunotherapy, 21 (32%) patients received an alternative treatment. The following therapies were used: regorafenib (n = 5), lenvatinib (n = 5), ramucirumab (n = 4), radiation (n = 4), sorafenib (n = 2), cabozantinib (n = 2), capecitabine (n = 2), gemcitabine plus cisplatin (n = 1), microwave ablation (n = 1) and SIRT (n = 1).

3.2. Efficacy {#apt15245-sec-0014}
-------------

Fifty‐four patients had at least one follow‐up imaging and were therefore available for radiological tumour response assessment (nivolumab, n = 30; pembrolizumab, n = 24). Of the 11 subjects not available for response assessment, 9 patients died before the first radiological evaluation and 2 patients were lost to follow‐up. In the nivolumab group, no patient had complete response (CR) and 5 (15%) participants achieved partial response (PR), resulting in an overall response rate (ORR) of 15%. Ten (29%) patients showed stable disease (SD) and 15 (44%) subjects had progressive disease at first radiological evaluation. The disease control rate (DCR) was 44%. In the pembrolizumab‐treated patients, 0 and 3 (10%) participants achieved complete response and partial response, respectively. Fourteen (45%) patients had stable disease and 7 (23%) individuals showed progressive disease. The overall response rate and disease control rate were 10% and 55% respectively. The overall response rate and disease control rate for the whole cohort were 12% and 49% respectively (Table [2](#apt15245-tbl-0002){ref-type="table"}). Of 54 patients with at least one follow‐up imaging, 52 patients were evaluable for hyperprogression (nivolumab, n = 28; pembrolizumab, n = 24), of which 4 (8%) subjects were classified as having hyperprogressive disease (nivolumab, n = 2 (7%); pembrolizumab, n = 2 (8%)).

###### 

Radiological response according to mRECIST and survival

                         Nivolumab           Pembrolizumab        All patients
  ---------------------- ------------------- -------------------- --------------------
  Best response                                                   
  CR                     0                   0                    0
  PR                     5 (15%)             3 (10%)              8 (12%)
  SD                     10 (29%)            14 (45%)             24 (37%)
  PD                     15 (44%)            7 (23%)              22 (34%)
  Not evaluable          4 (12%)             7 (23%)              11 (17%)
  ORR (CR+PR)            15%                 10%                  12%
  DCR (CR+PR+SD)         44%                 55%                  49%
  PFS, median (95% CI)   4.3 (2.0‐6.7) mo    5.6 (1.1‐10.1) mo    4.6 (3.0‐6.2) mo
  TTP, median (95% CI)   4.6 (1.9‐7.4) mo    6.4 (3.4‐9.5) mo     5.5 (3.5‐7.4) mo
  OS, median (95% CI)    9.0 (5.5‐12.5) mo   11.0 (7.4‐14.5) mo   11.0 (8.2‐13.8) mo
  1‐year survival rate   38%                 44%                  42%

CR, complete response; DCR, disease control rate; mRECIST, modified Response Evaluation Criteria in Solid Tumours; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease; TTP, time to progression.

John Wiley & Sons, Ltd

Overall, 35 (54%) patients had radiological disease progression and 36 (55%) participants died during follow‐up. Median time to progression was 5.5 (95% CI, 3.5‐7.4) months for the whole cohort (Figure [2](#apt15245-fig-0002){ref-type="fig"}), 4.6 (95% CI, 1.9‐7.4) months for nivolumab and 6.4 (95% CI, 3.4‐9.5) months for pembrolizumab (Figure [3](#apt15245-fig-0003){ref-type="fig"}, Table [2](#apt15245-tbl-0002){ref-type="table"}). Progression‐free survival was 4.6 (95% CI, 3.0‐6.2) months for the whole group (Figure [4](#apt15245-fig-0004){ref-type="fig"}), and 4.3 (95% CI, 2.0‐6.7) months and 5.6 (95% CI, 1.1‐10.1) months for nivolumab and pembrolizumab respectively (Figure [5](#apt15245-fig-0005){ref-type="fig"}, Table [2](#apt15245-tbl-0002){ref-type="table"}). Median overall survival was 11.0 (95% CI, 8.2‐13.8) months for the whole cohort (Figure [6](#apt15245-fig-0006){ref-type="fig"}), 9.0 (95% CI, 5.5‐12.5) months for nivolumab, and 11.0 (95% CI, 7.4‐14.5) months for pembrolizumab (Figure [7](#apt15245-fig-0007){ref-type="fig"}, Table [2](#apt15245-tbl-0002){ref-type="table"}).

![Kaplan‐Meier curve showing time to progression for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy](APT-49-1323-g002){#apt15245-fig-0002}

![Kaplan‐Meier curves showing time to progression for nivolumab‐ and pembrolizumab‐treated patients](APT-49-1323-g003){#apt15245-fig-0003}

![Kaplan‐Meier curve showing progression‐free survival for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy](APT-49-1323-g004){#apt15245-fig-0004}

![Kaplan‐Meier curves showing progression‐free survival for nivolumab‐ and pembrolizumab‐treated patients](APT-49-1323-g005){#apt15245-fig-0005}

![Kaplan‐Meier curve showing overall survival for the whole cohort of patients treated with programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy](APT-49-1323-g006){#apt15245-fig-0006}

![Kaplan‐Meier curves showing overall survival for nivolumab‐ and pembrolizumab‐treated patients](APT-49-1323-g007){#apt15245-fig-0007}

Median OS for patients with partial response or stable disease was 16.2 (95% CI, 9.1‐23.3) months and was significantly longer compared to that of patients with progressive disease, which was 7.4 (95% CI, 6.3‐8.5; *P* = 0.039) months (Figure [8](#apt15245-fig-0008){ref-type="fig"}).

![Kaplan‐Meier curves showing overall survival for patients treated with PD‐1‐targeted immunotherapy according to radiological tumour response (partial response (PR)/stable disease (SD) vs progressive disease (PD))](APT-49-1323-g008){#apt15245-fig-0008}

3.3. Safety {#apt15245-sec-0015}
-----------

Twenty‐five (39%) patients experienced at least one adverse event (AE). Most common adverse events were infections (n = 7; 11%), rash (n = 6; 9%), pruritus (n = 3; 5%), fatigue (n = 3; 5%), diarrhoea (n = 3; 5%) and hepatitis (n = 3; 5%). All cases of hepatitis were treated with corticosteroids. Eleven (17%) patients developed adverse events of higher grade (grade ≥ 3). Adverse events observed in nivolumab‐ and pembrolizumab‐treated patients are shown in Table [3](#apt15245-tbl-0003){ref-type="table"}. One patient died due to an infection; a relationship to pembrolizumab is unlikely but cannot be excluded. A dose delay due to adverse events was required in 6 (18%) patients treated with nivolumab and in 11 (36%) participants receiving pembrolizumab. Steroids or immunosuppressive drugs were used to treat an adverse event in 5 (15%) nivolumab‐ and 5 (16%) pembrolizumab‐treated subjects.

###### 

Adverse events

                            Nivolumab, n = 34   Pembrolizumab, n = 31   All patients, n = 65                      
  ------------------------- ------------------- ----------------------- ---------------------- -------- --------- --------
  Infection                 1 (3%)              1 (3%)                  6 (19%)                1 (3%)   7 (11%)   2 (3%)
  Rash                      2 (6%)              ---                     4 (13%)                ---      6 (9%)    ---
  Pruritus                  ---                 ---                     3 (10%)                ---      3 (5%)    ---
  Fatigue                   ---                 ---                     3 (10%)                ---      3 (5%)    ---
  Hepatitis                 2 (6%)              2 (6%)                  1 (3%)                 1 (3%)   3 (5%)    3 (5%)
  Diarrhoea                 ---                 ---                     3 (10%)                ---      3 (5%)    ---
  Myalgia/Myositis          1 (3%)              1 (3%)                  1 (3%)                 ---      2 (3%)    1 (2%)
  Amylase/Lipase increase   ---                 ---                     2 (6%)                 1 (3%)   2 (3%)    1 (2%)
  Vasculitis                ---                 ---                     2 (6%)                 2 (6%)   2 (3%)    2 (3%)
  Mucositis                 ---                 ---                     2 (6%)                 ---      2 (3%)    ---
  Paraesthesia              ---                 ---                     1 (3%)                 1 (3%)   1 (2%)    1 (2%)
  Arthritis                 ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Thyreoiditis              1 (3%)              ---                     ---                    ---      1 (2%)    ---
  Bronchiolitis             ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Dyspnoea                  ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Pain                      ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Nausea                    ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Renal                     ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Allergic reaction         ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Gastric ulcer             ---                 ---                     1 (3%)                 ---      1 (2%)    ---
  Variceal bleeding         1 (3%)              1 (3%)                  ---                    ---      1 (2%)    1 (2%)

John Wiley & Sons, Ltd

3.4. Efficacy and safety according to Child‐Pugh stage {#apt15245-sec-0016}
------------------------------------------------------

As the number of patients with Child‐Pugh stage C was too low (n = 5) for meaningful analysis, we excluded these patients and only compared the efficacy and safety of immunotherapy in patients with Child‐Pugh stage A and B. Overall response rate and disease control rate for Child‐Pugh A vs B was 9% vs 14% (*P* = 0.438) and 56% vs 46% (*P* = 0.947) respectively. Median time to progression was 4.8 (95% CI, 2.4‐7.2) months for Child‐Pugh A and 5.5 (95% CI, 1.5‐9.4) months for Child‐Pugh B (*P* = 0.511). Similarly, there was no difference in median progression‐free survival, which was 4.4 (95% CI, 1.2‐7.7) months for Child‐Pugh A and 4.6 (95% CI, 1.4‐7.9) months for Child‐Pugh B (*P* = 0.333). Median overall survival was 16.7 (95% CI, 8.2‐25.2) months for Child‐Pugh stage A and 8.6 (95% CI, 4.8‐12.4) months for Child‐Pugh B (*P* = 0.065) (Table [S2](#apt15245-sup-0001){ref-type="supplementary-material"}).

In terms of safety, there was no difference regarding the number of patients who developed any grade (Child‐Pugh A vs B, n = 10 (31%) vs n = 12 (43%); *P* = 0.352) or high‐grade (Child‐Pugh A vs B, n = 5 (16%) vs n = 5 (18%); *P* = 1.000) adverse events. Adverse events according to Child‐Pugh stage are shown in Table [S3](#apt15245-sup-0001){ref-type="supplementary-material"}.

3.5. Efficacy and safety according to systemic line of immunotherapy {#apt15245-sec-0017}
--------------------------------------------------------------------

As the number of patients who received immunotherapy as first (n = 9) or fourth (n = 3) line of systemic treatment was low, we grouped patients who received immunotherapy as first‐ or second‐line (group 1) and those in whom immunotherapy was used as third‐ or fourth‐line of systemic treatment (group 2).

Overall response rate and disease control rate for group 1 vs 2 was 11% vs 14% (*P* = 1.000) and 50% vs 48% (*P* = 0.901) respectively. Median time to progression was 5.6 (95% CI, 3.0‐8.3) months for group 1 and 4.8 (95% CI, 1.5‐8.1) months for group 2 (*P* = 0.452). Median progression‐free survival was 4.3 (95% CI, 0.9‐7.8) months for group 1 and 4.8 (95% CI, 1.8‐7.8) months for group 2 (*P* = 0.652). Median overall survival was 11.0 (95% CI, 5.7‐16.3) months for group 1 and 10.1 (95% CI, 7.4‐12.7) months for group 2 (*P* = 0.893) (Table [S4](#apt15245-sup-0001){ref-type="supplementary-material"}).

In terms of safety, the number of patients who developed any grade (Group 1 vs 2, n = 12 (33%) vs n = 13 (45%); *P* = 0.344) or high‐grade (Group 1 vs 2, n = 6 (17%) vs n = 5 (17%); *P* = 1.000) adverse events was similar between group 1 and 2.

4. DISCUSSION {#apt15245-sec-0018}
=============

We demonstrate that PD‐1‐targeted immunotherapy with nivolumab or pembrolizumab showed promising efficacy and mild toxicity in a real‐world cohort of patients with advanced stage HCC. Efficacy and safety results were comparable between Child‐Pugh A and B patients, even though median overall survival was shorter in Child‐Pugh B patients (16.7 vs 8.6 months). Overall survival of patients with stable disease or partial response was significantly longer than that of subjects with progressive disease (16.2 vs 7.4 months).

Two phase II studies tested nivolumab and pembrolizumab in patients with intermediate‐advanced stage HCC. The CheckMate 040 study, an open‐label, noncomparative, phase I/II trial, tested nivolumab in sorafenib‐naïve (n = 80) and ‐experienced (n = 182) patients with HCC and Child‐Pugh class A.[19](#apt15245-bib-0019){ref-type="ref"} Nivolumab was well‐tolerated with fatigue, pruritus, rash and diarrhoea being the most common adverse events. Overall response rate was 23% in sorafenib‐naïve and 19% in sorafenib‐pretreated patients according to RECISTv1.1 assessed by investigators. Responses were durable, independent of PD‐L1 expression, and translated into an encouraging survival with a median overall survival of 28.6 months in sorafenib‐naïve and around 15 months in sorafenib‐experienced patients. The few patients with a complete or partial response had an excellent outcome with 18‐ and 45‐months survival rates of 100% and about 90% respectively.[19](#apt15245-bib-0019){ref-type="ref"}, [24](#apt15245-bib-0024){ref-type="ref"}, [25](#apt15245-bib-0025){ref-type="ref"} Based on these promising data, nivolumab was conditionally approved for HCC previously treated with sorafenib in the United States in 2017. Recently published data from the KEYNOTE‐224 trial,[20](#apt15245-bib-0020){ref-type="ref"} a nonrandomised, open‐label phase II study investigating pembrolizumb in sorafenib‐pretreated patients (n = 104) with Child‐Pugh stage A showed similar results with an overall response rate of 17%, a median progression‐free survival of 4.9 months, and a median overall survival of 12.9 months. Again, fatigue, pruritus, diarrhoea and rash were the most frequent side effects.[20](#apt15245-bib-0020){ref-type="ref"} Pembrolizumab also received FDA approval in the United States recently. Nivolumab as the first‐line treatment and pembrolizumab in second‐line are currently investigated in ongoing phase III trials of advanced HCC (nivolumab: NCT02576509; pembrolizumab: NCT02702401, NCT03062358).

Monoclonal antibodies are not metabolized by the liver but eliminated predominantly via uptake and catabolism by the reticuloendothelial system and target tissue.[26](#apt15245-bib-0026){ref-type="ref"} This could make the pharmacokinetic profile of immune checkpoint inhibitors more predictable even in patients with advanced liver cirrhosis.[15](#apt15245-bib-0015){ref-type="ref"} However, the CheckMate 040[19](#apt15245-bib-0019){ref-type="ref"} and the KEYNOTE‐224[20](#apt15245-bib-0020){ref-type="ref"} study only included Child‐Pugh A patients, a common practice in HCC trials in order to minimise the confounding effect of death from liver cirrhosis on overall outcome.[27](#apt15245-bib-0027){ref-type="ref"} In our study, a significant proportion of patients had Child‐Pugh stage B or C (51%) though. The number of patients with any grade and high‐grade adverse events was similar between Child‐Pugh class A and B suggesting that immunotherapy can be administered safely even in patients with more advanced liver function impairment. Even though efficacy in terms of overall response rate, time to progression and progression‐free survival was similar between Child‐Pugh A and B patients, OS was shorter in the Child‐Pugh B group, and prognosis of patients with advanced HCC and Child‐Pugh stage B is often limited.[28](#apt15245-bib-0028){ref-type="ref"} Thus, the decision to use systemic treatment in decompensated patients should be evaluated carefully on a case‐by‐case basis, taking into account other comorbidities and---most importantly---the potential for recompensation.

In contrast to the phase II trials of nivolumab[19](#apt15245-bib-0019){ref-type="ref"} and pembrolizumab[20](#apt15245-bib-0020){ref-type="ref"} that used immunotherapy as first‐ or second‐line treatment, we administered checkpoint blockers as third or even fourth line in nearly half of patients (45%). Despite the intensive pretreatment, immunotherapy led to a disease stabilization in about half of the patients. However, in contrast to the CheckMate 040[19](#apt15245-bib-0019){ref-type="ref"} and the KEYNOTE‐22[20](#apt15245-bib-0020){ref-type="ref"} study, which used RECIST v1.1 to assess their primary endpoint, none of our patients had complete response, even though we used mRECIST criteria, which have a higher sensitivity to capture response to treatment compared to conventional RECIST.[1](#apt15245-bib-0001){ref-type="ref"}

Efficacy and safety was similar between patients who received immunotherapy as first‐/second‐line treatment compared to those in whom immunotherapy was used in third‐/fourth‐line. Most agents used prior to immunotherapy in our cohort (eg, sorafenib, regorafenib) are known for their anti‐angiogenic effects.[29](#apt15245-bib-0029){ref-type="ref"}, [30](#apt15245-bib-0030){ref-type="ref"} This is of particular interest as hypoxia, often induced by anti‐angiogenic agents, promotes an immunosuppressive tumour microenvironment, inter alia by an upregulation of immune checkpoint molecules.[31](#apt15245-bib-0031){ref-type="ref"}, [32](#apt15245-bib-0032){ref-type="ref"} Indeed, sorafenib intensified tumour hypoxia and increased tumoural PD‐L1 expression in experimental models of HCC.[33](#apt15245-bib-0033){ref-type="ref"}, [34](#apt15245-bib-0034){ref-type="ref"} Thus, immunotherapy may be particularly attractive following or combined with anti‐vascular endothelial growth factor (VEGF)‐targeted therapies. In line, preliminary data of pilot studies testing the combination of lenvatinib plus pembrolizumab (n = 26) and bevacizumab combined with atezolizumab (n = 68) showed encouraging response rates of 42% and 34% respectively.[35](#apt15245-bib-0035){ref-type="ref"}, [36](#apt15245-bib-0036){ref-type="ref"}

Hyperprogressive disease---an increased tumour growth rate during treatment---is a new pattern of progression that was recently reported for patients treated with PD‐1‐/PD‐L1‐targeted immunotherapy.[23](#apt15245-bib-0023){ref-type="ref"}, [37](#apt15245-bib-0037){ref-type="ref"}, [38](#apt15245-bib-0038){ref-type="ref"} Four (8%) patients in our cohort had hyperprogression during immunotherapy. This is in line with a previous study that reported hyperprogressive disease in 9% of patients with advanced cancers,[37](#apt15245-bib-0037){ref-type="ref"} but lower compared to recurrent and/or metastatic head and neck cancer (29%)[38](#apt15245-bib-0038){ref-type="ref"} and advanced non‐small‐cell lung cancer (13.8%) treated with PD‐1/PD‐L1 blockers.[23](#apt15245-bib-0023){ref-type="ref"} Notably, hyperprogressive disease was defined differently in these studies as there is currently no consensus on the optimal definition.[23](#apt15245-bib-0023){ref-type="ref"}, [37](#apt15245-bib-0037){ref-type="ref"}, [38](#apt15245-bib-0038){ref-type="ref"} The underlying mechanisms for hyperprogressive disease are unknown, but it was hypothesised that major immune reactions, promotion of tumour cell proliferation, immune compensatory mechanisms and prior irradiation may play a role in hyperprogression with PD‐1‐/PD‐L1‐targeted therapy.[37](#apt15245-bib-0037){ref-type="ref"}, [38](#apt15245-bib-0038){ref-type="ref"}

Despite the retrospective nature and the lack of a control group, the strength of our study is the provision of unique real‐world data on a patient cohort usually excluded from clinical trials (ie, Child‐Pugh B/C, multiple lines of systemic pretreatment). These data represent important new information on subgroups of patients frequently found in everyday clinical practice and tumour board discussions. Additionally, to our knowledge, this is the first study that evaluated hyperprogression with PD‐1 blockers in HCC.

In conclusion, PD‐1‐targeted immunotherapy with nivolumab or pembrolizumab was safe in patients with advanced HCC including patients with Child‐Pugh class B. Immunotherapy was associated with a good survival in those who achieved disease stabilization, while prognosis of patients with progressive disease remained rather poor. This highlights the need for biomarkers to select those patients most likely to benefit from treatment. The combination of immunotherapy and targeted therapies may have the potential to further improve the outcome. A closer radiological follow‐up within the first weeks after initiation of immunotherapy may be considered in order to detect those patients with early progression or hyperprogressive disease. Phase III trials testing nivolumab and pembrolizumab in the first‐ and second‐line setting are ongoing and their results are eagerly awaited.
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